18. September 2025|
AI
|3 months agoRoche Expands Liver Treatment Portfolio with $3.5B Acquisition
Basel-based Roche acquires California's 89bio for $3.5 billion, strengthening its position in liver and cardiovascular disorder treatments.
AI
Generated IllustrationKey Takeaways
AI
- Roche is acquiring California-based 89bio for $3.5 billion total
- Initial acquisition sum is $2.4 billion with additional payments up to $1.1 billion
- The deal includes pegozafermin, currently in phase III clinical trials
- 89bio employees will join Roche's pharmaceutical workforce
By The Numbers
52%
Premium over 60-day weighted average price
79%
Premium over closing price on September 17
$6.00
Per share offer
They Said
"The transaction should be completed before the end of the year"